Browsing by Author "Marinho, A."
Now showing 1 - 10 of 16
Results Per Page
Sort Options
- Acute Kidney Injury in the Critically Ill PatientPublication . Herrera-Gutiérrez, M.; Seller-Pérez, G.; Maynar-Moliner, J.; Sánchez-Izquierdo-Riera, J.; Marinho, A.; Do pico, J.
- Anti-Ro52 Antibodies and Interstitial Lung Disease in ConnectiveTissue Diseases Excluding SclerodermaPublication . Ferreira, J.; Almeida, I.; Marinho, A.; Cerveira, C.; Vasconcelos, C.The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in myositis, scleroderma, and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial, and studies are lacking for clarifying the association of anti-Ro52 with interstitial lung disease (ILD) in connective tissue diseases (CTD). Objectives. To determine if anti-Ro52 antibodies are associated with ILD in CTD other than scleroderma. Methods. Singlecenter, retrospective study based on immunoblotting panel analysis and patients clinical records. Results. In our connective tissue disease cohort, 162 patients had immunoblotting panels with anti-Ro52 reactivity analysis, 41 (25,3%) had inclusion criteria. Among the 41 selected sera, 85.4% (n = 35) had anti-Ro52 reactivity. The prevalence of ILD in the positive anti-Ro52 antibodies was 71.4% (n = 25), and 16.7% (n = 1) in the negative anti-Ro52 group (P = 0.018). Overall sensitivity (96.2%), specificity (83.3%), positive (71.4%) and negative (83.3%) predictive values of anti-Ro52 antibodies to determine ILD in CTD is detailed in this study. Conclusion. Ro52 autoantibodies are associated with ILD in CTD excluding scleroderma. We suggest that the presence of anti-Ro52 reactivity in CTD should increase the clinician curiosity for the search of ILD.
- Antineutrophil cytoplasmatic antibody positive systemic vasculitis in a patient treated with propylthiouracilPublication . Silva, S.; Ferreira, J.; Carvalho, S.; Seabra, F.; Marinho, A.
- Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?Publication . Ferreira, J.; Almeida, I.; Marinho, A.; Cerveira, C.; Vasconcelos, C.Abstract Introduction: The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in myositis, scleroderma and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial. Studies are lacking in clarifying the association of anti-Ro52 with pulmonary involvement in scleroderma. Objectives: To determine if anti-Ro52 antibodies are associated with pulmonary involvement (interstitial, indirect pulmonary hypertension, or both) in scleroderma. Methods: Single center, retrospective study based on immunoblotting panel analysis and patients clinical records. Pulmonary manifestations were sub-grouped in: 1) interstitial (alveolitis and/or fibrosis), 2) pulmonary artery systolic pressure (PASP) ≥40 mmHg plus interstitial pulmonary disease, and 3) isolated PASP≥40 mmHg (purely vascular). Results: Our scleroderma cohort included 200 patients, of which 137 had immunoblotting panels with anti-Ro52 reactivity analysis. The search was conducted between January 2010 and July 2011. The frequency of pulmonary manifestations in patients with positive anti-Ro52 antibodies was 67.7% (n=31), and 60% (n=24) in the negative anti-Ro52 group, showing no significant differences between groups (p=0.621). Still no significant differences were found when pulmonary manifestations were evaluated according to the subgroups (p=0.525). Sensitivity, specificity, positive and negative predictive values of anti-Ro52 reactivity for determining pulmonary involvement in scleroderma were low. Conclusion: No association was found between positive anti-Ro52 antibodies and pulmonary involvement in scleroderma.
- Avaliação da lesão renal aguda no doente críticoPublication . Gil, R.; Marinho, A.
- Avaliação das necessidades energéticas no doente críticoPublication . Marinho, A.; Pinho, J.; Cançado, L.; Oliveira, M.; Marinho, R.; Martins, F.Introdução: Os doentes críticos são um grupo de do- entes francamente hipermetabólicos que necessitam de um suporte nutricional adequado às suas necessidades. Objectivos: Verificar o melhor método para determinar as neces- sidades energéticas de doentes críticos. Material e métodos: Estudo transversal analítico no qual foram recolhidos dados demográficos, determinado o consumo energético quer por calorimetria indirecta, quer pela fórmula de Harris-Benedict e além disso calculado o fator de stress de pacientes internados entre 2004 e 2009. Resultados: Incluíram- se neste estudo 139 doentes (33% feminino, 67% masculino). Foram efetuadas 298 medidas pela calorimetria indireta, com tempo útil médio de 9 horas, que foram compa- radas às necessidades energéticas calculadas a partir da equação de Harris-Benedict. Encontraram-se diferenças significativas entre os resultados obtidos. O consumo energético mensurado foi 27,9 Kcal/kg (mediana), e quando comparado à equação de Harris-Benedict, evidenciou-se um valor subestimado em 25% (7 Kcal/kg). A mediana do fator de stress encontrado para a correção da fórmula de Harris- Benedict foi de 1,31. Discussão e conclusão: Embora exista uma variabilidade do consumo energético nesses doentes, a fórmula de Harris-Benedict, quando associada a um fator stress entre 1,25 – 1,35, poderá ser um método eficaz na avaliação das necessidades nutricionais. Por outro lado, pode-se optar também por uma abordagem mais simplificada, utilizando valores energéticos entre 25 a 30 Kcal por quilograma de peso. Obviamente, a calorimetria indireta continua a ser o “gold standard’’ da avaliação do consumo energético, já que nos permite adequar as necessidades energéticas em função do consumo energético in- dividual de acordo com o gasto real de cada doente.
- Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injuryPublication . Vesconi, S.; Cruz, D.; Fumagalli, R.; Kindgen-Milles, D.; Monti, G.; Marinho, A.; Mariano, F.; Formica, M.; Marchesi, M.; René, R.; Livigni, S.; Ronco, C.Introduction The optimal dialysis dose for the treatment of acute kidney injury (AKI) is controversial. We sought to evaluate the relationship between renal replacement therapy (RRT) dose and outcome. Methods We performed a prospective multicentre observational study in 30 intensive care units (ICUs) in eight countries from June 2005 to December 2007. Delivered RRT dose was calculated in patients treated exclusively with either continuous RRT (CRRT) or intermittent RRT (IRRT) during their ICU stay. Dose was categorised into more-intensive (CRRT ≥ 35 ml/kg/hour, IRRT ≥ 6 sessions/week) or less-intensive (CRRT < 35 ml/kg/hour, IRRT < 6 sessions/week). The main outcome measures were ICU mortality, ICU length of stay and duration of mechanical ventilation. Results Of 15,200 critically ill patients admitted during the study period, 553 AKI patients were treated with RRT, including 338 who received CRRT only and 87 who received IRRT only. For CRRT, the median delivered dose was 27.1 ml/kg/hour (interquartile range (IQR) = 22.1 to 33.9). For IRRT, the median dose was 7 sessions/week (IQR = 5 to 7). Only 22% of CRRT patients and 64% of IRRT patients received a more-intensive dose. Crude ICU mortality among CRRT patients were 60.8% vs. 52.5% (more-intensive vs. less-intensive groups, respectively). In IRRT, this was 23.6 vs. 19.4%, respectively. On multivariable analysis, there was no significant association between RRT dose and ICU mortality (Odds ratio (OR) moreintensive vs. less-intensive: CRRT OR = 1.21, 95% confidence interval (CI) = 0.66 to 2.21; IRRT OR = 1.50, 95% CI = 0.48 to 4.67). Among survivors, shorter ICU stay and duration of mechanical ventilation were observed in the more-intensive RRT groups (more-intensive vs. less-intensive for all: CRRT (median): 15 (IQR = 8 to 26) vs. 19.5 (IQR = 12 to 33.5) ICU days, P = 0.063; 7 (IQR = 4 to 17) vs. 14 (IQR = 5 to 24) ventilation days, P = 0.031; IRRT: 8 (IQR = 5.5 to 14) vs. 18 (IQR = 13 to 35) ICU days, P = 0.008; 2.5 (IQR = 0 to 10) vs. 12 (IQR = 3 to 24) ventilation days, P = 0.026). Conclusions After adjustment for multiple variables, these data provide no evidence for a survival benefit afforded by higher dose RRT. However, more-intensive RRT was associated with a favourable effect on ICU stay and duration of mechanical ventilation among survivors. This result warrants further exploration. Trial Registration Cochrane Renal Group (CRG110600093).
- Estimating Kidney Function in the Critically Ill PatientsPublication . Seller-Pérez, G.; Herrera-Gutiérrez, M.; Maynar-Moliner, J.; Sánchez-Izquierdo-Riera, J.; Marinho, A.; do Pico, J.Glomerular filtration rate (GFR) is an accepted measure for assessment of kidney function. For the critically ill patient, creatinine clearance is the method of reference for the estimation of the GFR, although this is often not measured but estimated by equations (i.e., Cockroft-Gault or MDRD) not well suited for the critically ill patient. Functional evaluation of the kidney rests in serum creatinine (Crs) that is subjected to multiple external factors, especially relevant overhydration and loss of muscle mass. The laboratory method used introduces variations in Crs, an important fact considering that small increases in Crs have serious repercussion on the prognosis of patients. Efforts directed to stratify the risk of acute kidney injury (AKI) have crystallized in the RIFLE or AKIN systems, based in sequential changes in Crs or urine flow. These systems have provided a common definition of AKI and, due to their sensitivity, have meant a considerable advantage for the clinical practice but, on the other side, have introduced an uncertainty in clinical research because of potentially overestimating AKI incidence. Another significant drawback is the unavoidable period of time needed before a patient is classified, and this is perhaps the problem to be overcome in the near future.
- LINFOPENIA T CD4 NO LUPUS ERITEMATOSO SISTÉMICOPublication . Ferreira, S.; Vasconcelos, J.; Marinho, A.; Farinha, F.; Almeida, I.; Correia, J.; Barbosa, P.; Mendonça, T.; Vasconcelos, C.Abstract: Background: Systemic Lupus Erythematosus (SLE) is an inflammatory chronic disease characterized by the presence of autoantibodies, immunocomplex production and organ injury. Several alterations of the immune system have been described, namely of CD4 T cells, with particular focus on regulatory subgroup. Objective: Quantify peripheral CD4 T cells in a population of patients with SLE and correlate it with lupus activity, affected organs, therapeutics and infections. Methods: Retrospective study involving all SLE patients seen in the clinical immunology outpatient clinic of the Hospital Geral Santo António, Porto that has done some peripheral blood flow cytometry study. Results: Twenty-nine patients have been evaluated, 16 were taking glucocorticoids and six immunossupressors. The mean SLEDAI at the study time was nine and the ECLAM was three. Thirty-one percent of the patients had leukopenia, 76% lymphocytopenia and the same number CD4 depletion. Fifty-five percent of the patients had CD4 levels lower than 500/mm3, 31% lower than 200/mm3. All patients with SLEDAI ?20 and ECLAM ?4 had CD4 counts inferior to 500/mm3 and all patients with inactive disease had CD4 superior to 500/mm3. There have been three opportunistic infections: cryptococcal meningitis, pulmonary aspergilosis, Pneumocystis jirovecii pneumonia, all in patients with CD4 counts lower than 500/mm3. Conclusion: Decreased CD4 T cells counts have been very common in this study population. There is an inverse relation between CD4 cells counts and disease activity. Opportunistic infections occurred in patients with severe CD4 depletion. Keywords: Systemic Lupus Erythematosus; CD4 T Lymphocytes; Lymphocytopenia; SLE Activity; Opportunistic infections
- A nossa regra de ouro na doença de Behçet: tratar a manifestação clínicaPublication . Ferrão, C.; Almeida, I.; Marinho, A.; Vasconcelos, C.; Correia, J.A Doença de Behçet (DB) é uma vasculite sistémica que pode ser definida na fronteira entre a doença autoimune e autoinflamatória. A sua etiopatogenia ainda não é completamente conhecida, embora saibamos que contribuem factores genéticos (Antigénios de Histocompatibilidade/ HLA, por exemplo) e ambienciais (maior prevalência em zonas específicas do globo). Há células implicadas no processo patológico (neutrófilos, macrófagos, linfócitos T reguladores) e outros componentes (factor de necrose tumoral/ TNF, interleucinas) do sistema imune. As formas clínicas da DB são muito variadas, quer na gravidade, quer nos órgãos atingidos: Behçet Mucocutâneo, Behçet Ocular, Vasculobehçet, Neurobehçet, Behçet Intestinal, Behçet Cardíaco. Independentemente dos mecanismos imuno-inflamatórios subjacentes às diversas apresentações clínicas, a terapêutica tem de ser adaptada a cada uma delas. A nossa série de DB, coligida ao longo de 20 anos, é representativa de todo o espectro clínico de DB e consideramos útil fazer uma resenha atual da terapêutica indicada, caldeando os dados da literatura, com a nossa experiência.